Data presented at a conference yesterday suggest AbbVie's all-oral regimen may be more effective than Gilead's at curing the virus in certain patients, but will it confer an edge?
Kynamro's slow start, coupled with competition, has prompted Sanofi to add sales reps.
Promotions and hires for manufacturers, agencies and regulatory
Ceci Zak, Chief operating officer, Diversified Agency Services, Omnicom
Jack Hyndman, Creative, Fingerpaint